Prevalence of mupirocin resistant staphylococcus aureus isolates among patients admitted to a tertiary care hospital

North American Journal of Medical Sciences

Volumn 6, Issue 8, 2014, Pages 403-407

  Chaturvedi, Parul ^a   Singh, Amit Kumar ^b   Shukla, Snehanshu ^a   Agarwal, Loveleena ^a  

^a Dr KNS Memorial Institute of Medical Sciences Gadia Barabanki   (India)

^b Major SD Singh Medical College and Hospital   (India)

Author keywords

High Level; Low Level; MRSA; MuH; MuL; Mupirocin resistance

Indexed keywords

EID: 84906489981     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.139293     Document Type: Article

References (26)

1. Joshi S, Ray P, Manchanda V, Bajaj J, Chitnis DS, Gautam V, et al. Methicillin-resistant Staphylococcus aureus (MRSA) in India: Prevalence and susceptibility pattern. Indian J Med Res 2013;137:363-9.
2. Dubey D, Rath S, Sahu MC, Pattnaik L, Debata NK, Padhy RN. Surveillance of infection status of drug resistant Staphylococcus aureus in an Indian teaching hospital. Asian Pac J Trop Dis 2013;3:133-42.
3. Kaur H, Purwar S, Saini A, Kaur H, Karadesai SG, Kholkute SD, Roy S. Status of Methicillin-resistant Staphylococcus aureus Infections and Evaluation of PVL Producing Strains in Belgaum, South India. JKIMSU 2012;1:43-51.
4. Sivaraman K, Venkataraman N, Cole AM. Staphylococcus aureus Nasal Carriage and its Contributing Factors. Future Microbiol 2009;4:999-1008.
5. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005;5:751-62.
6. Rayner C, Munckhof WJ. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern Med J 2005;35:S3-16.
7. Klutymans J, van Balkum A, Verbrughi H. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms and associated risk. Clin Microbiol Rev 1997;10:505-20.
8. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002;49:999-1005.
9. Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: Past, present, and future. Clin Infect Dis 2014;58:S20-7.
10. Hogue JS, Buttke P, Braun LE, Fairchok MP. Mupirocin resistance related to increasing mupirocin use in clinical isolates of methicillin-resistant staphylococcus aureus in a pediatric population. J Clin Microbiol 2010;48:2599-600.
11. Yanagisawa T, Lee JT, Wu HC, Kawakami M. Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. J Biol Chem 1994;269:24304-9.
12. de Oliveira NE, Cardozo AP, Marques De A, dos Santos KR, Giambiagi-deMarval M. Interpretive criteria to differentiate low- and high-level mupirocin resistance in Staphylococcus aureus. J Med Microbiol 2007;56:937-9.
13. Patel JB, Gorwitz RJ, Jernigan JB. Mupirocin resistance. Clin Infect Dis 2009;49:935-41.
14. Hudson IR. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: A review of recent experience. J Hosp Infect 1994;27:81-98.
15. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: Does mupirocin remain effective? Infect Control Hosp Epidemiol 2003;24:342-6.
16. Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007;44:178-85.
17. Robicsek A, Beaumont JL, Thomson RB Jr, Govindarajan G, Peterson LR. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: Impact on infection risk. Infect Control Hosp Epidemiol 2009;30:623-32.
18. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI document M100-S23. Vol 33. Wayne: Clinical and Laboratory Standards Institute; 2013. p. 74-85.
19. Gordon RJ, Lowy FD. Pathogenesis of methicillinresistant staphylococcus aureus infection. Clin Infect Dis 2008;46:S350-9.
20. Hurdle JG, O Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother 2005;56:1166-8.
21. Arora S, Devi P, Arora U, Devi B. Prevalence of methicillinresistant staphylococcus aureus (MRSA) in a tertiary care hospital in northern India. J Lab Physicians 2010;2:78-81.
22. Singh AK, Venkatesh V, Singh M. Mupirocin resistance in clinical isolates of Staphylococcus aureus in a tertiary care hospital set up in north India. Int J Med Res Health Sci 2013;2:840-7.
23. Gadepalli R, Dhawan B, Mohanty S, Kapil A, Das BK, Chaudhry R, et al. Mupirocin resistance in Staphylococcus aureus in an Indian hospital. Diagn Microbiol Infect Dis 2007;58:125-7.
24. Gadepalli R, Dhawan B, Mohanty S, Kapil A, Das BK, Chaudhry R. Inducible clindamycin resistance in clinical isolates of Staphylococcus aureus. Indian J Med Res 2006;123:571-3.
25. Gupta V, Datta P, Rani H, Chander J. Inducible clindamycin resistance in Staphylococcus aureus: A Study from North India. J Postgrad Med 2009;55:176-9.
26. Prabhu K, Rao S, Rao V. Inducible clindamycin resistance in staphylococcus aureus isolated from clinical samples. J Lab Physicians 2011;3:25-7.